STICHTING BIOMEDICAL PRIMATE RESEARCH CENTER

Their core work

BPRC is a specialized Dutch research center focused on vaccine development and testing using primate models. They provide preclinical evaluation platforms for vaccines against major infectious diseases including HIV, tuberculosis, rabies, and flaviviruses. Their work spans the vaccine development pipeline from discovery through preclinical testing, with strong capabilities in immunology, virology, and vaccine quality control. They also contribute to building European vaccine research infrastructure, supporting both human and veterinary vaccinology.

What they specialise in

How they've shifted over time

In the early period (2015–2017), BPRC focused on disease-specific vaccine development — HIV therapeutics, tuberculosis, and rabies — with deep involvement in immunology platforms, trial design, and data integration. From 2017 onward, their focus shifted toward vaccine infrastructure and broader vaccinology frameworks, culminating in the large TRANSVAC2 and TRANSVAC-DS projects that support both human and veterinary vaccine R&D across Europe. This evolution signals a move from being a participant in individual disease programs to becoming a structural pillar of the European vaccine development ecosystem.

BPRC is positioning itself as a core infrastructure provider for European vaccinology, moving beyond single-disease projects toward platform-level contributions that serve multiple vaccine programs.

How they like to work

BPRC operates exclusively as a consortium participant, never as coordinator, which is consistent with their role as a specialized research facility contributing preclinical expertise to larger programs. They work in sizable European consortia — 133 unique partners across 23 countries indicates broad network integration rather than narrow repeat partnerships. This makes them a reliable, experienced consortium partner who understands large multi-site projects and can plug into diverse teams without friction.

BPRC has collaborated with 133 unique partners across 23 countries, giving them one of the broader networks in European vaccine research. Their connections span academic institutions, public health bodies, and vaccine manufacturers across the EU and beyond.

What sets them apart

BPRC occupies a rare niche: a primate research center with deep vaccine evaluation capabilities that few European institutions can match. Their combination of immunology platforms, preclinical testing capacity, and involvement in vaccine infrastructure projects makes them a go-to partner when a consortium needs rigorous animal model data for vaccine candidates. For coordinators building a vaccine-related proposal, BPRC brings both the technical capability and an established track record across multiple disease areas — TB, HIV, rabies, flaviviruses — that demonstrates versatility within their specialization.

Highlights from their portfolio

• TRANSVAC2
  Their largest project by far (EUR 2.6M) — building the core European Vaccine R&D Infrastructure covering both human and veterinary applications.
• EHVA
  EUR 1M contribution to the European HIV Vaccine Alliance, demonstrating BPRC's role in high-profile disease-specific vaccine platforms with strong immunology capabilities.
• RABYD-VAX
  Dual-target rabies/flavivirus infectious DNA vaccine — an unusually innovative approach combining two pathogen targets in one candidate.